Bone Biologics: Bone Biologics Reports Progress With NB1 Clinical Program

(marketscreener.com) Bone Biologics Corporation , a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion. Following Human Research Ethics Committee approval last year in Australia for the multicenter, prospective, randomized pilot clinical trial, the...https://www.marketscreener.com/quote/stock/BONE-BIOLOGICS-CORPORATIO-120796041/news/Bone-Biologics-Reports-Progress-With-NB1-Clinical-Program-46073493/?utm_medium=RSS&utm_content=20240301